Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT01137838
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
To compare the proportion of rheumatoid arthritis (RA) patients prescribed opioids, benzodiazepines, and antidepressants before versus after starting each of the following biologics: abatacept, infliximab, etanercept, adalimumab, utilizing an administrative claims database.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1810
Inclusion Criteria
- ICD 9 diagnosis RA 714.0
- Documented first biologic prescription ("index" prescription) for abatacept, infliximab, etanercept, or adalimumab
- Continuous therapy (gap between scripts no greater than 150% days supply) for minimum 6 months from index
- Prescription claims data available for 6 months before and 12 months after index biologic prescription
- Continuous eligibility for 6 months before and 12 months after index biologic prescription
Read More
Exclusion Criteria
- Prescription claims for another biologic during the observation period (including rituximab and anakinra)
- Prescriptions not continuous for at least 6 months
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of RA patients prescribed opioids, benzodiazepines, and antidepressants 7-12 months after index biologic prescription
- Secondary Outcome Measures
Name Time Method Prevalence of depression and/or anxiety (ICD-9 diagnosis code) 7-12 months after index biologic prescription